anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
An array platform for three-dimensional cell culturing and drug testing and screening is disclosed. In the array platform, a hydrogel-cell mixture injection area is used to inject kinds of hydrogel-cell mixtures. Cell observation areas are connected to the hydrogel-cell mixture injection area. Electrodes are disposed under the cell observation areas and automatic cell quantification and three-dimensional cell co-arrangement of the kinds of hydrogel-cell mixtures in the cell observation areas through the electrodes to imitate a structure of body&#39;s tissues. A drug injection area is used to inject kinds of drugs. Drug combination generators respectively correspond to the cell observation areas and are connected to the drug injection area. The drug combination generators all have micro-flow channel structure and used to generate drug combinations according to the kinds of drugs.
A professional total health services provider and leader specialized in integrative medicine incorporating data collection tools, analysis tools, and health adjustment procedures. The data collection tools first detect, extract, monitor, and/or receive data from the patient. This data is then provided to the analysis tools according to various integrated medicine methods, from which patient reports with visual diagrams are created and shared with the patient. Each patient&#39;s data and relative analysis are individually saved in the respective patient&#39;s records and, as a whole, anonymously stored in a database. The anonymous data in this database undergoes comprehensive analysis, utilizing master analysis tools, where the results are employed to produce reliable study reports. Medical facility franchises under the provider send the collected patient data to a central facility for extensive analysis and reporting, after which the appropriate health adjustment procedures are then suggested to and performed on each patient.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a powder-containing solid cosmetic which does not belong to a powder solid cosmetic and an oil gel solid cosmetic, belongs to a region between both the cosmetics, and has an excellent color-rendering property.  &lt;P&gt;SOLUTION: This solid cosmetic comprising (1) a cross-linked organopolysiloxane and (2) fine particles is characterized by containing an oily ingredient having flowability at 1 atmospheric pressure and at 25°C in an amount of 20 to 50 mass%. The cross-linked organopolysiloxane is preferably a cross-linked methylpolysiloxane. The content of the cross-linked organopolysiloxane is preferably 3 to 10 mass%. The content of the fine particles is preferably 40 to 75 mass%. The fine particles are preferably titanium mica which may be subjected to a surface treatment and colored. It is preferable that the viscosity of the mixture of the cross-linked organopolysiloxane with the oily ingredient having flowability at 1 atmospheric pressure and at 25°C is 400 to 1,000 mP×sec at 20°C.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
1446141 Cinnamamides and hydrocinnamamides KISSEI YAKUHIN KOGYO KK 16 Jan 1974 [18 Jan 1973] 02102/74 Heading C2C The invention comprises cinnamamides and hydrocinnamimides of the Formula I wherein R 1  and R 2  each are H or C 1-4  alkyl; R 3  and R 4  are H or may be combined together to form another carbon to carbon bond; each X is OH, halogen, C 1-4  alkyl or C 1-4  alkoxy; and n is 1 to 3, or (X) n  may also constitute where a and b are 0 or 1 and c is 2 to 10 wherein the said group is attached to adjacent carbon atoms of the benzene ring to form a ring, and pharmaceutically acceptable salts thereof, and their preparation. The compounds are prepared by reacting the appropriate cinnamic acids or hydrocinnamic acids or reactive functional derivatives thereof with the corresponding aminobenzoic acids or esters thereof, and, if necessary, hydrolysing the resulting products. Compounds of the Formula I above in which R&lt;SP&gt;3&lt;/SP&gt; and R&lt;SP&gt;4&lt;/SP&gt; are combined together to form a carbon to carbon bond may also be prepared by halogenating hemi esters of malonic acid, reacting the resulting 2-(haloformyl)acetic acid esters with aminobenzoic acids or esters thereof, hydrolysing the resulting products, and condensing the resulting N-(carboxyphenyl)malonamic acids using the Knoevenogel reaction with benzaldehydes of the Formula X 4 - (4 - Acetoxycinnamoylamino)benzoic acid and 3 - (4 - acetoxy - 3 - methoxycinnamoylamino)benzoic acid are obtained by reacting the appropriate cinnamoyl chlorides with the corresponding aminobenzoic acids. Methyl N - (3,4 - dimethoxycinnamoyl)- anthranilate is prepared by reacting methyl anthranilate with 3,4-dimethoxycinnamic acid. Pharmaceutical compositions, suitable for oral or parenteral administration, contain the above acids or salts thereof in admixture with pharmaceutically acceptable carriers or diluents. The compounds possess antiallergic activity.
PURPOSE: To obtain an effective adjuvant composition capable of being used for preparation of animal or human vaccine. CONSTITUTION: This adjuvant composition is obtained by formulating (A) at least one kind of synthetic hydrophobic lipopolysaccharide capable or incapable of supplying an anion group, preferably sulfate group, preferably having 0.2-4 average ratio to saccharide group, &lt;=9, especially &lt;=4 hydrophilic-hydrophobic balance (HLB) with (B) a interface-forming component, preferably a liquid which is immiscible with an aqueous phase (e.g. oil originating from animals or plants, preferably squalane) or a solid which is insoluble in the aqueous phase [e.g. Al(OH)3 or AlPO4 ] as essential components and as necessary, further, adding (C) an aqueous solute, e.g. a salt solution, a phosphoric acid buffer solution or pure water thereto. The composition can be used as vaccine by mixing with immunogen.
The invention relates to a traditional Chinese medicine composite suppository for treating constipation, prepared by the following raw materials by weight parts: fructus cannabis 5-55 parts, sesame 1-50 parts, peach kernel 5-40 parts, schizonepeta spike 10-60 parts. The fructus cannabis, sesame and peach kernel are mixed and pressed to produce oil, and then the produced oil is washed using hot water until no floc in the produced oil and then the produced oil is filtered for standby; the schizonepeta spike is subjected to wet distillation and the oil layer is separated and extracted and then mixed with the above produced oil and then the ground substance is added into the mixture to produce suppository and finally the traditional Chinese medicine composite suppository is subjected to thermal sealing and packaging. The traditional Chinese medicine composite suppository has obvious curative effect, based on &#39;syndrome differentiation and treatment&#39; principle of traditional Chinese medicine syndrome. The long time clinical practice shows that: the traditional Chinese medicine composite suppository has stable curative effect on constipation due to blood-deficiency and body-fluid little. The traditional Chinese medicine composite suppository not only relieves symptom but also radically treats the constipation. The traditional Chinese medicine composite suppository is mainly used for treating stool constipation due to oldness and debility, blood-deficiency and body-fluid little after serious illness and delivery. The traditional Chinese medicine composite suppository does not comprises any western medicine with low side effect and conquers the defects of western medicine of large side effect and higher cost, namely an economic medicine with definite curative effect.
NEW MATERIAL:The esterified product of sterol and lactic acid or carboxylic acid obtained by the intermolecular oligoesterification of lactic acid of formula (n is 0 or integer of &gt;=1). EXAMPLE:Cholesteryl lactate. USE:Raw material of cosmetics and external remedy. PROCESS:For example, lactic acid or a carboxylic acid of formula obtained by the intermolecular oligoesterification of lactic acid is charged together with a sterol (e.g. cholesterol) in a reactor, mixed with tin chloride, etc. as a catalyst and toluene, etc. as a refluxing solvent, and reacted by heating at 140-220 deg.C under thorough agitation. After the completion of the reaction, the catalyst is removed by filtration, and the filtrate is decolorized with activated clay, etc. and deodorized by blasting steam at 150-220 deg.C under reduced pressure to obtain esterified product. Cosmetics such as cold cream, etc. can be prepared by mixing the ester with liquid praffin, white vaseline, beeswax, water, perfume, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To propose a technology allowing high-accuracy specification of erroneous notation inside an electronic document (text) and corresponding right notation even in a field (e.g. a medical field) wherein a morpheme-analyzing dictionary is not completed and sufficient morpheme analysis accuracy is impossible to obtain.  &lt;P&gt;SOLUTION: Based on processing results of a morpheme analysis means 2 and a word likelihood calculation means 3, an erroneous notation correction candidate specification means by preparer 4 extracts a character string having low appearance probability only inside a report written by a specific doctor as a candidate of the right notation. An erroneous notation correction means by preparer 6 extracts a character string having high appearance probability only inside a report written by a specific doctor as a candidate of the erroneous notation to the respective obtained character strings. Similarity is calculated to all combinations of the respective character strings by a word similarity calculation means 5, and the erroneous notation correction means 6 specifies a combination having high similarity as an erroneous notation word and its correction word.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an α2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant. Tests by the Applicants have shown that at least some TCAA drugs can relieve neuropathic pain to a limited extent, but at the doses required to relieve pain, they cause adverse side effects, and any pain relief is relatively brief and short-lived. However, when a TCAA drug such as ethopropazine is administered together with an α2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another&#39;s neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. Accordingly, this drug combination can provide safe and effective relief of neuropathic pain and possibly other types of chronic and/or intractable pain, at dosages which are so low that they do not pose serious risks of adverse side effects.
A substantially non-aqueous aerosol insecticidal and/or bactericidal and/or fungicidal and/or insect repellent spray composition comprises a normally gaseous propellant maintained in liquid phase under pressure in an aerosol container equipped with a spray valve, an insecticidal and/or bactericidal and/or fungicidal and/or insect-repellent ingredient (the &#34;active ingredient&#34;) dissolved in said liquid propellent and a powdered material capable of absorbing said active ingredient when dissolved in said propellent, said powdered absorbent material being insoluble in said propellent and adapted to be sprayed from the container by said propellent and to act when so sprayed as a carrier for said active ingredient upon evaporation of the propellent.  The powder may be talc or starch. The active ingredient may be allethrin, pyrethrum plus either sesame oil or piperonyl butoxide, D.D.T., undecylenic acid, oleum vetiveriae, oleum quassiae, or N,N-diethyl-m-toluamide. Optional ingredients include kerosene, thymol, benzoic acid, and perfumes. The propellent may be a fluorinated hydrocarbon.ALSO:A substantially non-aqueous aerosol insecticidal and/or bactericidal and/or fungicidal and/or insect repellent spray composition comprises a normally gaseous propellant maintained in liquid phase under pressure in an aerosol container equipped with a spray valve, an insecticidal and/or bactericidal and/or fungicidal and/or insect repellent ingredient (the &#34;active ingredient&#34;) dissolved in said liquid propellant and a powdered material capable of absorbing said active ingredient when dissolved in said propellent, said powdered absorbent material being insoluble in said propellent and adapted to be sprayed from the container by said propellent and to act when so sprayed as a carrier for said active ingredient upon evaporation of the propellent.  The powder may be talc or starch.  The active ingredient may be allethrin, pyrethrum plus either sesame oil or piperonyl butoxide, D.D.T., undecylenic acid, oleum vetiveriae, oleum quassiae, or N,N-diethyl-m-toluamide.  Optional ingredients include kerosene, thymol, benzoic acid, and perfumes.  The propellent may be a fluorinated hydrocarbon.
Mutations in the leucine-rich repeat kinase (LRRK2) gene cause late-onset autosomal dominant Parkinson&#39;s disease (PD) with pleiomorphic pathology. Previously, we and others found that expression of mutant LRRK2 causes neuronal degeneration in cell culture. Here we used the GAL4/UAS system to generate transgenic  Drosophila  expressing either wild-type (WT1) human LRRK2 or LRRK2-G2019S, the most common mutation associated with PD. Expression of either WT1 human LRRK2 or LRRK2-G2019S in the photoreceptor cells caused retinal degeneration. Expression of WT1 LRRK2 or LRRK2-G2019S in neurons produced adult-onset selective loss of dopaminergic neurons, locomotor dysfunction, and early mortality. Expression of mutant G2019S-LRRK2 caused a more severe parkinsonism-like phenotype than expression of equivalent levels of WT1 LRRK2. Treatment with L-DOPA improved mutant LRRK2-induced locomotor impairment but did not prevent the loss of tyrosine hydroxylase (TH)-positive neurons. To our knowledge, this is the first in vivo “gain-of-function” model which recapitulates several key features of LRRK2-linked human parkinsonism. These flies may provide a useful model for studying LRRK2-linked pathogenesis and for future therapeutic screens for PD intervention.
1503444 Topical compositions MINNESOTA MINING &amp; MFG CO 23 March 1976 [24 March 1975] 11672/76 Heading A5B Non-greasy occulusive compositions for topical application to the skin as cosmetics or ointment bases comprise 40 to 90% by weight of a viscous base comprising solid petroleum, animal oils, mineral oils and/or synthetic oils, in which the oils have been thickened with wax and/or a hydrocarbon polymer, and 10 to 60% by weight of an ointment forming powder which is non-irritating to human skin, solid at 25C, insoluble in water and the other components of the composition, has a number average dimension of less than 30 microns and is substantially non-absorbent to the viscous base at temperatures below 50C, the ointment forming powder having been mixed with the viscous base at a temperature of less than 50C. The ointment forming powder may be a polyolefin such as polyethylene, hydrated magnesium silicate or hydrated aluminium silicate. The thickening agent may be a polyolefin e.g. polyethylene or cholesterol. The composition may also contain a styrene copolymer and/or a consistency modifier. The composition may be in the form of an ointment; lotion or cream. The composition may contain a medicament such as a corticosteroid e.g. dexamethasonet-butyl acetate, bacitracin, neomycin sulphate or polymyxin B sulphate.
1. An oligonucleotide having the sequence 5&#39;CTT CCT GTC TGA TGG CTT CT3&#39; (SEQ ID NO: 4), inhibiting the activity of IL-8 receptor. 2. The oligonucleotide having the sequence 5&#39; GAA AGT TTG TGC CTT ATG GA 3&#39; (SEQ ID NO:2), inhibiting the activity of IL-8. 3. The oligonucleotides of claims 1 or 2 wherein at least a portion of the backbone is modified from the normally occuring phosphodiesterase configuration. 4. The oligonucleotides of claims 1 or 2 wherein at least one of the sugars is modified from the normal ribose configuration. 5. The oligonucleotides of claims 1 or 2 wherein at least a portion of the backbone is modified from the normally occuring phosphodiesterase configuration and at least one of the sugars is modified from the normal ribose configuration. 6. A method for treating a cancer which is at least partially mediated by IL-8 receptor said method comprising the steps of: providing a pharmaceutical containing oligonucleotide of claim 1, and administering to a patient an effective amount of an oligonucleotide. 7. The method of claim 6 wherein the step of administering comprises intratumoral injection. 8. The method of claim 6 wherein the step of administering comprises intravenous injection. 9. A method of treating a cancer, which at least partially mediated by IL-8, said method comprising the steps of: providing a pharmaceutical containing oligonucleotide of claim 2, and administering to a patient an effective amount of an oligonucleotide. 10. The method of claim 9 wherein the step of administering comprises intratumoral injection. 11. The method of claim 9 wherein the step of administering comprises intravenous injection.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an external preparation for decreasing fat and a fat decreasing apparatus, both locally decreasing fat by a simple means such as sticking/coating, etc.  &lt;P&gt;SOLUTION: The external preparation for decreasing fat contains at least one of lipolysis components such as capsaicin, its homologues, its derivatives, or a nonylic acid vanillylamide and of adipogenesis suppressive components. The external preparation includes an agent drug including a base material and a drug layer which is formed on the base material, contacts with skin, and includes a lipolysis component and/or an adipogenesis suppressive component. The base material can include a material capable of transmitting ultrasonic sound, a perforate or a large number of small openings, and an ultrasonic acoustic binder which makes ultrasonic wave impregnated into the base material to be transmissive. When the drug layer of the attachable external preparation contacts with a skin or is applied to the skin as a coated external preparation containing a lipolysis component and/or an adipogenesis suppression component, a physical stimulus granting means imparting physical irritation from the body surface can be used at the same time. The physical stimulus granting means for the living body is at least one of ultrasonic wave, electromagnetic wave, or mechanical vibration.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide food and drink containing an enhancing agent of volume of semen, total number of sperm and virility of the male of a human being and an animal.  &lt;P&gt;SOLUTION: A prepared product for a human being or livestock contains at least one type of xanthophyll such as astaxanthin. The effective dose of the prepared product is administered to the male of a human being or livestock. It is preferable to let the astaxanthin exist in a form of esterification with fatty acid, for instance a form of algae dining produced by culture of algae Haematococcus sp. Furthermore, at least one type of xanthophyll such as astaxanthin is used for preparing the prepared product for a human being or livestock to enhance volume of semen, total number of sperm and virility of the male of a human being and an animal.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
An inhalation system including a fluid transfer member, a valve member, a cartridge assembly, and a mouthpiece, and a method of use thereof are provided. The valve member connects to an open end of the fluid transfer member. The cartridge assembly, positioned within the valve member, includes a substance holder and an absorbent member accommodated within a cartridge for containing and absorbing an inhaling substance. When the valve member connects to a vaporizer, the vaporizer heats the absorbent member to vaporize and release an inhaling fluid into the fluid transfer member. When the valve member connects to the mouthpiece, the valve member receives and transfers the inhaling fluid vapor from the fluid transfer member to a user&#39;s mouth via the mouthpiece. The locking mouthpiece assembly allows authentication of the user prior to releasing the inhaling fluid to the user&#39;s mouth.
1487980 Xanthan gum suspensions MERCK &amp; CO Inc 31 Oct 1975 [4 Nov 1974] 45423/75 Headings C3U and C3F Pumpable xanthan gum suspensions are obtained by mixing 20-50% (w./v.) of the xanthan gum and 0-5 to 10% (w./v.) of a hydroxyalkyl cellulose derivative in a C 1-5 alcohol solvent or in an alcohol-water solvent system. The suspension is preferably made by adding the xanthan gum to a previously prepared blend of the hydroxyalkyl cellulose derivative and the solvent. The cellulose derivative preferably has the formula where R is the cellulose residue and R11 is a straight or branched C 3 -C 5 alkyl chain, e.g. hydroxypropyl cellulose, hydroxypropyl methyl cellulose, or hydroxybutyl methyl cellulose.
The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array, and in particular an Aβ1-6 peptide-VLP-composition. More specifically, the invention provides a composition comprising a virus-like particle and at least one Aβ 1-6 peptide bound thereto. The invention also provides a process for producing the conjugates and the ordered and repetitive arrays, respectively. The compositions of the invention are useful in the production of vaccines for the treatment of Alzheimer&#39;s disease and as a pharmaccine to prevent or cure Alzheimer&#39;s disease and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.  &lt;P&gt;SOLUTION: Immune related diseases can be treated by suppressing or enhancing the immune response. Molecules that enhance the immune response stimulate or potentiate the immune response to an antigen. Molecules which stimulate the immune response can be used therapeutically where enhancement of the immune response would be beneficial. Alternatively, molecules that suppress the immune response attenuate or reduce the immune response to an antigen (e.g., neutralizing antibodies) can be used therapeutically where attenuation of the immune response would be beneficial (e.g., inflammation). Accordingly, PRO polypeptides, agonists and antagonists thereof are also useful to prepare medicines and medicaments for the treatment of immune-related and inflammatory diseases. Such medicines and medicaments comprise a therapeutically effective amount of a PRO polypeptide, agonist or antagonist thereof with a pharmaceutically acceptable carrier.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT